Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
Globe Newswire•23/10/2026•08:30 ET
0
Key Highlights
- ➤Microbot Medical (MBOT) executives will attend SIR EDGE 2026 and ACIR’s annual conference.
- ➤Company is expanding its national sales footprint and engaging hospital Value Analysis Committees.
- ➤Prior similar events generated leads that remain in Microbot’s sales funnel.
- ➤LIBERTY is FDA-cleared, single-use, remotely operated for peripheral endovascular procedures.
Expert Statements
Harel Gadot, Chairman, CEO and President of Microbot Medical
“We believe these opportunities to engage with hundreds of potential users are invaluable, and we have benefited from prior similar events to generate new leads, many of which we continue to manage through the sales funnel, including the VAC process.”
Harel Gadot, Chairman, CEO and President of Microbot Medical
“This event allows us to meet jointly with physicians and administrators, share the positive user experience and feedback that we have already received, and take the next step of setting up demonstrations to initiate the sales process.”
HINGHAM, Mass., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that key executives and members of the Company’s commercial team will be attending the SIR EDGE 2026 conference in Louisville, Kentucky, providing an opportunity for the Company to engage with prospective customers.
SIR EDGE 2026 is designed to provide interventional radiologists with practical, case-based education focused on real-world clinical decision-making and patient care.
Get started
Create a free account to read the full story.